|
|
Article: Pharmos Announces Results from Phase 2a Trial of Cannabinor for Nociceptive Pain in Third Molar Dental Extraction Model.
- Article from:
- M2 Presswire
- Article date:
- April 24, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-24 April 2007-Headline Maker: Pharmos Announces Results from Phase 2a Trial of Cannabinor for Nociceptive Pain in Third Molar Dental Extraction Model(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:24042007
Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Activity on the NASDAQ market has brought this company to the attention of our research team. Pharmos Corporation (Nasdaq: PARS), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the ...